News-Wuhan Createrna Science and Technology Co.,Ltd.

Home
Scientific R&D
- Research Ability
- Pipeline
News Activity
- News Center
About Us
Join Us
- Careers
- Recruitment

CN

News Center

News

2026-06-11

China’s First Domestically Developed Oral CFB Inhibitor: Createrna’s Lanoracopan Hydrochloride Tablets Approved for Marketing

2026-05-12

Createrna Receives IND Approval for Novel Class 1 Drug QR055453D Tablets for Idiopathic Pulmonary Fibrosis (IPF)
2026-02-13

Createrna’s MY008211A Tablets (Lanoracopan Hydrochloride) Achieve Primary Efficacy Endpoint in Phase III Trial in Complement Inhibitor-Naïve PNH Patients
2025-10-15

Createrna’s CFB Inhibitor MY008211A Tablets Granted Priority Review Designation and New Drug Application Accepted by China’s NMPA
2025-03-14

QR Science and Technology Donates RMB 100 Million to Huazhong University of Science and Technology for Medical Research Advancement
2024-11-28

Createrna Announces Phase II Clinical Results of MY008211A in Treatment-Naïve PNH Patients at ASH 2024
2023-09-28

Createrna Receives Capital Injection from Well-known Investment Institutions
2023-06-25

Createrna Announces Completion of Series A Financing at Its Strategic Investment Press Conference in Wuhan
2022-07-17

MY004567 tablets was approved by the FDA US. for clinical trials implied

1